LILLY AXID FOR GERD PROMOTIONS TO MANAGED CARE CITED IN FDA WARNING LETTER; COST-EFFECTIVENESS, COMPARATIVE CLAIMS ALSO DEEMED MISLEADING BY AGENCY
Executive Summary
Lilly's promotions of Axid (nizatidine) for gastroesophageal reflux disease to managed care customers have drawn a warning letter from FDA's Division of Drug Marketing, Advertising & Communications.